Adiso Therapeutics
Concord
About Adiso Therapeutics
Adiso develops medications to treat inflammatory diseases. Current treatment paradigms are either insufficient to halt disease progression or burden the patient with significant safety concerns. To address these issues, we are developing a novel pipeline of small molecules and single strain live biotherapeutic products (SS-LBP), both of which have novel mechanisms of action.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $60.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2022)
- Website: adisotx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/adiso-therapeutics-122460 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.